Search results
Results from the WOW.Com Content Network
Drugs developed by Wyeth (31 P) Pages in category "Drugs developed by Pfizer" The following 200 pages are in this category, out of approximately 240 total.
In June 2022, Roivant and Pfizer unveiled Priovant Therapeutics. [22] Priovant was established in September 2021 through a transaction between Roivant and Pfizer, [23] in which Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25% equity ownership interest in ...
Pfizer is part of major stock indices like the S&P 100 and S&P 500, having major institutional investors. [4] Pfizer is one of the top pharmaceutical companies in the United States, with a market capitalization of $150.35 billion as of December 31, 2024. It ranks fifth among U.S. pharma companies.
Pfizer's shares were up 2.6% at $29.30 in afternoon trading. Pfizer made the disclosure on Wednesday in a filing with the Securities and Exchange Commission. Pfizer rolls out another cost-cutting ...
The drug layer is a liquid compartment containing a drug solution or suspension separated by the adhesive layer. The drug reservoir is totally encapsulated in a shallow compartment molded from a drug-impermeable metallic plastic laminate, with a rate-controlling membrane made of a polymer like vinyl acetate on one surface. [ 24 ]
The Seagen deal, as well as its $4 billion cost-cutting plan, are a key part of Pfizer's post-COVID growth stra Pfizer lifts profit forecast as CEO sees reason for optimism in 2024 Skip to main ...
Generally, drugs outlined within the ATC code D should be included in this category. Please see WP:PHARM:CAT for more information. Subcategories.
In November 2021, Pfizer submitted an application to the US Food and Drug Administration (FDA) for emergency use authorization for the co-packaged medication. [ 68 ] [ 69 ] [ 70 ] The authorization was granted in December 2021, for people aged twelve years of age or older who are infected with COVID‑19 and are at risk.